Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer.

The identification of a blood-based diagnostic marker is a goal in many areas of medicine, including the early diagnosis of prostate cancer. We describe the use of averaged differential display as an efficient mechanism for biomarker discovery in whole blood RNA. The process of averaging reduces the...

Full description

Bibliographic Details
Main Authors: V Uma Bai, Ok Hwang, George W Divine, Evelyn R Barrack, Mani Menon, G Prem-Veer Reddy, Clara Hwang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3321043?pdf=render
_version_ 1819195560780890112
author V Uma Bai
Ok Hwang
George W Divine
Evelyn R Barrack
Mani Menon
G Prem-Veer Reddy
Clara Hwang
author_facet V Uma Bai
Ok Hwang
George W Divine
Evelyn R Barrack
Mani Menon
G Prem-Veer Reddy
Clara Hwang
author_sort V Uma Bai
collection DOAJ
description The identification of a blood-based diagnostic marker is a goal in many areas of medicine, including the early diagnosis of prostate cancer. We describe the use of averaged differential display as an efficient mechanism for biomarker discovery in whole blood RNA. The process of averaging reduces the problem of clinical heterogeneity while simultaneously minimizing sample handling.RNA was isolated from the blood of prostate cancer patients and healthy controls. Samples were pooled and subjected to the averaged differential display process. Transcripts present at different levels between patients and controls were purified and sequenced for identification. Transcript levels in the blood of prostate cancer patients and controls were verified by quantitative RT-PCR. Means were compared using a t-test and a receiver-operating curve was generated. The Ring finger protein 19A (RNF19A) transcript was identified as having higher levels in prostate cancer patients compared to healthy men through the averaged differential display process. Quantitative RT-PCR analysis confirmed a more than 2-fold higher level of RNF19A mRNA levels in the blood of patients with prostate cancer than in healthy controls (p = 0.0066). The accuracy of distinguishing cancer patients from healthy men using RNF19A mRNA levels in blood as determined by the area under the receiving operator curve was 0.727.Averaged differential display offers a simplified approach for the comprehensive screening of body fluids, such as blood, to identify biomarkers in patients with prostate cancer. Furthermore, this proof-of-concept study warrants further analysis of RNF19A as a clinically relevant biomarker for prostate cancer detection.
first_indexed 2024-12-23T02:14:42Z
format Article
id doaj.art-447207c9a92c4946a0cd36e4786f7b2b
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-23T02:14:42Z
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-447207c9a92c4946a0cd36e4786f7b2b2022-12-21T18:03:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0174e3487510.1371/journal.pone.0034875Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer.V Uma BaiOk HwangGeorge W DivineEvelyn R BarrackMani MenonG Prem-Veer ReddyClara HwangThe identification of a blood-based diagnostic marker is a goal in many areas of medicine, including the early diagnosis of prostate cancer. We describe the use of averaged differential display as an efficient mechanism for biomarker discovery in whole blood RNA. The process of averaging reduces the problem of clinical heterogeneity while simultaneously minimizing sample handling.RNA was isolated from the blood of prostate cancer patients and healthy controls. Samples were pooled and subjected to the averaged differential display process. Transcripts present at different levels between patients and controls were purified and sequenced for identification. Transcript levels in the blood of prostate cancer patients and controls were verified by quantitative RT-PCR. Means were compared using a t-test and a receiver-operating curve was generated. The Ring finger protein 19A (RNF19A) transcript was identified as having higher levels in prostate cancer patients compared to healthy men through the averaged differential display process. Quantitative RT-PCR analysis confirmed a more than 2-fold higher level of RNF19A mRNA levels in the blood of patients with prostate cancer than in healthy controls (p = 0.0066). The accuracy of distinguishing cancer patients from healthy men using RNF19A mRNA levels in blood as determined by the area under the receiving operator curve was 0.727.Averaged differential display offers a simplified approach for the comprehensive screening of body fluids, such as blood, to identify biomarkers in patients with prostate cancer. Furthermore, this proof-of-concept study warrants further analysis of RNF19A as a clinically relevant biomarker for prostate cancer detection.http://europepmc.org/articles/PMC3321043?pdf=render
spellingShingle V Uma Bai
Ok Hwang
George W Divine
Evelyn R Barrack
Mani Menon
G Prem-Veer Reddy
Clara Hwang
Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer.
PLoS ONE
title Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer.
title_full Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer.
title_fullStr Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer.
title_full_unstemmed Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer.
title_short Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer.
title_sort averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer
url http://europepmc.org/articles/PMC3321043?pdf=render
work_keys_str_mv AT vumabai averageddifferentialexpressionforthediscoveryofbiomarkersinthebloodofpatientswithprostatecancer
AT okhwang averageddifferentialexpressionforthediscoveryofbiomarkersinthebloodofpatientswithprostatecancer
AT georgewdivine averageddifferentialexpressionforthediscoveryofbiomarkersinthebloodofpatientswithprostatecancer
AT evelynrbarrack averageddifferentialexpressionforthediscoveryofbiomarkersinthebloodofpatientswithprostatecancer
AT manimenon averageddifferentialexpressionforthediscoveryofbiomarkersinthebloodofpatientswithprostatecancer
AT gpremveerreddy averageddifferentialexpressionforthediscoveryofbiomarkersinthebloodofpatientswithprostatecancer
AT clarahwang averageddifferentialexpressionforthediscoveryofbiomarkersinthebloodofpatientswithprostatecancer